Cancer
Conditions
Brief summary
This study aimed to assess the efficacy of cryotherapy in controlling Peripheral Neuropathy in cancer children
Detailed description
Peripheral neuropathy is a serious condition characterized by symmetrical, distal damage to the peripheral nerves that may be caused by several classes of drugs, including chemotherapeutic agents. Chemotherapy-induced peripheral neuropathy (CIPN) is an adverse effect estimated to occur in up to 40% of patients undergoing chemotherapy, with its incidence increasing in patients being treated with multiple agents. Pharmacists play a pivotal role in the prevention and management of CIPN by recommending evidence-based pharmacologic and non pharmacologic strategies appropriate for the individual patient.Peripheral neuropathy (PN) is a systemic disease characterized by symmetrical, distal damage to the peripheral nerves that negatively impacts patient quality of life (QOL). Prolonged symptoms associated with PN can cause pain, interfere with functional ability (e.g., dressing, driving, house-work), and disrupt emotional health.
Interventions
DEVICECryotherapy
Cryotherapy is a pain treatment that uses a method of localized freezing temperatures to deaden an irritated nerve. Cryotherapy is also used as a method of treating localized areas of some cancers (called cryosurgery), such as prostate cancer and to treat abnormal skin cells by dermatologists
Sponsors
Delta University for Science and Technology
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Masking description
Single (Outcomes Assessor) Blinding process to participants and care providers was impossible due to the nature of intervention therapy. Data were analyzed by an impartial statistician (outcomes assessor), referring to each arm with an encoded name: Group A (control group) and Group B (study group).
Eligibility
Sex/Gender
ALL
Age
8 Years to 17 Years
Healthy volunteers
No
Inclusion criteria
1. Their age will ranging from eight to seventeen years. 2. Children participated in this study will from both sexes. 3. Children receiving chemotherapy as medical treatment protocol 4. All children have polyneuropathy caused by chemotherapy.
Exclusion criteria
1. Children with Epilepsy. 2. Children with blood clotting disorder. 3. Children have Open wounds / broken skin 4. Children with severe cardiac disease 5. Uncooperative patients.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Nerve conduction studies (NCS) | nerve conduction velocity for sensory ulnar nerve at day 0 | nerve conduction velocity for sensory ulnar nerve |
Countries
Egypt
Contacts
Primary ContactWalaa E Heneidy, PHD
Outcome results
None listed